Search Within

Neeta Pandit-Taskar

  1. "Hematologic Malignancies, Division of"
Formats
  1. Meeting Abstract (27)
  2. Journal Article (16)
Groups
  1. Department of Medicine (43)
  2. Hematologic Malignancies, Division of (43)
  3. Molecular Imaging and Therapy Service (43)
  4. Radiology, Department of (43)
  5. GSK Faculty (27)
  6. Center for Hematologic Malignancies (26)

More Groups

People
  1. Steven Larson (23)
  2. Jorge Carrasquillo (15)
  3. Chaitanya Divgi (12)
  4. Howard Scher (11)
  5. Michael Morris (11)
  6. Susan Slovin (11)

More People

Years
  1. 2024 (2)
  2. 2023 (3)
  3. 2022 (3)
  4. 2021 (2)
  5. 2019 (2)
  6. 2016 (1)

More Years

Publications
  1. Blood (13)
  2. Journal of Clinical Oncology (12)
  3. Clinical Cancer Research (5)
  4. Journal of Nuclear Medicine (4)
  5. Cancer (2)
  6. European Journal of Nuclear Medicine and Molecular Imaging (2)

More Publications

Publishers
  1. American Society of Hematology (13)
  2. American Society of Clinical Oncology (12)
  3. American Association for Cancer Research (6)
  4. Society of Nuclear Medicine (4)
  5. Springer (3)
  6. Wiley Blackwell (2)

More Publishers

Results (43)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Noninvasive assessment of programmed-death ligand-1 (PD-L1) in esophagogastric (EG) cancer using (18)F-BMS-986229 PET
    Meeting Abstract

    Cytryn, S. L.; Pandit-Taskar, N.; Maron, S. B.; Gu, P.; Ku, G. Y.; Chou, J. F.; Capanu, M.; Feder, L.; Philemond, S.; Lyashchenko, S. K.; more...
    Journal of Clinical Oncology (2024)

    Fulltext@MSK | Save
  • (18)F-BMS-986229 PET to assess programmed-death ligand 1 status in gastroesophageal cancer
    Journal Article

    Cytryn, S. L.; Pandit-Taskar, N.; Lumish, M. A.; Maron, S. B.; Gu, P.; Ku, G. Y.; Chou, J. F.; Capanu, M.; Antoine, A.; Loegel, D.; more...
    Journal of Nuclear Medicine (2024)

    Fulltext@MSK | Save
  • High-dose targeted radiation with (131)I-apamistamab prior to HCT demonstrated a dose-response for durable complete remission in patients with R/R AML
    Meeting Abstract

    Litzow, M. R.; Chen, G.; Gyurkocza, B.; Nath, R.; Seropian, S.; Choe, H.; Abboud, C. N.; Koshy, N.; Tomlinson, B. K.; Abhyankar, S.; more...
    Blood (2023)

    Fulltext@MSK | Save
  • TITLE: A pilot study of 89Zr-DFO-REGN3767 anti-LAG-3 antibody positron emission tomography in patients with diffuse large B-cell lymphoma
    Meeting Abstract

    Pandit-Taskar, N.; Shutian, R.; Grkovski, M.; Schwartz, J.; Lyashchenko, S.; Cheung, K.; Uldrick, T.; Ma, D.; Giurleo, J.; Palomba, L.
    Journal of Nuclear Medicine (2023)

    Fulltext@MSK | Save
  • Determinants of survival with combined HER2 and PD-1 blockade in metastatic esophagogastric cancer
    Journal Article

    Maron, S. B.; Chatila, W.; Walch, H.; Chou, J. F.; Ceglia, N.; Ptashkin, R.; Do, R. K. G.; Paroder, V.; Pandit-Taskar, N.; Lewis, J. S.; more...
    Clinical Cancer Research (2023)

    Fulltext@MSK | Save
  • An ongoing pilot study of targeted radioimmunotherapy (131-I apamistamab) conditioning prior to CD19-targeted CAR T-cell therapy for relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma
    Meeting Abstract

    Geyer, M. B.; Cadzin, B.; Hosszu, K.; Senechal, B.; Spross, J. A.; Mark, A.; Desai, A.; Cathcart, E. R.; Palomba, M. L.; Pandit-Taskar, N.
    Blood (2022)

    Fulltext@MSK | Save
  • 1(8)F-FDG PET/CT for post-treatment surveillance imaging of patients with stage III Merkel cell carcinoma
    Journal Article

    Mahajan, S.; Barker, C. A.; Mauguen, A.; D’Angelo, S. P.; Yeh, R.; Pandit-Taskar, N.
    Journal of Nuclear Medicine (2022)

    Fulltext@MSK | Save
  • Treatment of patients with acute myeloid leukemia with the targeted alpha-particle nanogenerator (225)actinium-lintuzumab
    Journal Article

    Rosenblat, T. L.; McDevitt, M. R.; Carrasquillo, J. A.; Pandit-Taskar, N.; Frattini, M. G.; Maslak, P. G.; Park, J. H.; Douer, D.; Cicic, D.; Larson, S. M.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Iomab with adoptive cellular therapy (Iomab-ACT): A pilot study of 131-I apamistamab followed by CD19-targeted car T-cell therapy for patients with relapsed or refractory B-cell acute lymphoblastic leukemia or diffuse large B-cell lymphoma
    Meeting Abstract

    Geyer, M. B.; Cadzin, B.; Halton, E.; Kane, P.; Senechal, B.; Geoghegan, E. M.; Reddy, V.; Berger, M. S.; Ludwig, D.; Pandit-Taskar, N.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer
    Meeting Abstract

    Maron, S. B.; Chatila, W. K.; Walch, H. S.; Ptashkin, R.; Sabwa, S.; Ling, L.; Nagy, R.; Simmons, M.; Do, R. K. G.; Paroder, V.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save